Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

Jordi Ribera, Lurdes Zamora, Mireia Morgades, Susana Vives, Isabel Granada, Pau Montesinos, Inés Gómez-Seguí, Santiago Mercadal, Ramon Guàrdia, Josep Nomdedeu, Marta Pratcorona, Mar Tormo, Joaquín Martínez-Lopez, Jesús María Hernández-Rivas, Juana Ciudad, Alberto Orfao, José González-Campos, Pere Barba, Lourdes Escoda, Jordi EsteveEulàlia Genescà, Francesc Solé, Evarist Feliu, Josep Maria Ribera

Research output: Contribution to journalArticleResearch

4 Citations (Scopus)

Abstract

© 2019 Wiley Periodicals, Inc. Minimal residual disease (MRD) assessment is an essential tool in contemporary acute lymphoblastic leukemia (ALL) protocols, being used for therapeutic decisions such as hematopoietic stem cell transplantation in high-risk patients. However, a significant proportion of adult ALL patients with negative MRD still relapse suggesting that other factors (ie, molecular alterations) must be considered in order to identify those patients with high risk of disease progression. We have identified partial IKZF1 gene deletions and CDKN2A/B deletions as markers of disease recurrence and poor survival in a series of uniformly treated adolescent and adult Philadelphia chromosome-negative B-cell progenitor ALL patients treated according to the Programa Español de Tratamientos en Hematología protocols. Importantly, CDKN2A/B deletions showed independent significance of MRD at the end of induction, which points out the need for treatment intensification in these patients despite being MRD-negative after induction therapy.
Original languageEnglish
Pages (from-to)815-819
JournalGenes Chromosomes and Cancer
Volume58
DOIs
Publication statusPublished - 1 Nov 2019

Fingerprint

Dive into the research topics of 'Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this